Trials / Recruiting
RecruitingNCT07450976
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
A Phase IIa/IIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1904 for Injection | SHR-A1904 for injection, different doses. |
Timeline
- Start date
- 2026-03-25
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2026-03-05
- Last updated
- 2026-03-31
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07450976. Inclusion in this directory is not an endorsement.